Not professing skills in this area but attracted to company by its client list

Pfizer, Johnson&Johnson, Roche and Novartis all clients to name but a few

Company effectively reproduces human response to possible drugs, creams etc . Effectively builds a"virtual patient". Others do this but not sure they have the client list

Seems to get repeat business plus looks to be on c2x - 2.5x sales year just ended. IMHO too low for such a stock. Recent news in Feb all good and suggests on certain ventures they get some interest in new compunds developed

Listed above this price -- 85p --- this time last year. Results should be in next few weeks. Any thoughts?

thx for the comments. Will stay away from this now, as can't see good news or a profit for long time given they say an adjustment to business will be needed to cut costs